Skip to content
  • Saturday, 15 August 2026
  • 1:32 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Remepy’s Hybridopa, a Pioneer in AI-Driven Hybrid Drugs, Demonstrates Significant Efficacy in Parkinson’s Phase IIa Trial
Laboratory Automation & Robotics

Remepy’s Hybridopa, a Pioneer in AI-Driven Hybrid Drugs, Demonstrates Significant Efficacy in Parkinson’s Phase IIa Trial

Lana Keisha Jul 17, 2026 0

San Francisco, CA – May 2026 – Remepy, a burgeoning health technology startup at the vanguard of integrating pharmaceutical and…

Read More
Neuroscience & Brain Research

Existing Chronic Constipation Medication Demonstrates Significant Potential to Alleviate Lingering Cognitive Deficits in Post-Depression Recovery

Rifan Muazin Jul 16, 2026 0

While the clinical treatment of major depressive disorder has historically focused on stabilizing mood and emotional regulation, a significant portion…

Read More
Pharmaceutical R&D

Sanofi’s Nexviazyme Demonstrates Promising Results in Infants with Infantile-Onset Pompe Disease, Paving Way for Potential Label Expansion

Teuku Ryan Jul 1, 2026 0

Sanofi’s groundbreaking treatment for Pompe disease, Nexviazyme (avalglucosidase alfa), has achieved a significant milestone with the successful completion of the…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Retatrutide Demonstrates Superior Weight Loss Efficacy Amidst Elevated Side Effect Profile in Phase 3 Trials

Lana Keisha Jun 25, 2026 0

INDIANAPOLIS, IN – Eli Lilly and Company has announced groundbreaking Phase 3 trial results for its investigational drug, retatrutide, a…

Read More
Advanced Materials Science

Breakthrough in Nanoscale Thermal Engineering Demonstrates Record-Breaking Heat Transfer Control via Metamaterial Structures

Nila Kartika Wati Jun 25, 2026 0

A team of researchers from Carnegie Mellon University, in collaboration with experts from Stanford University and Purdue University, has published…

Read More
Laboratory Automation & Robotics

Eli Lilly’s Retatrutide Demonstrates Unprecedented Weight Loss with Notable Side Effect Profile in Phase 3 Trials

Lana Keisha May 29, 2026 0

Eli Lilly and Company’s investigational drug, retatrutide, a groundbreaking triple hormone receptor agonist, has delivered an average weight loss of…

Read More
Pharmaceutical R&D

Foundayo Demonstrates Efficacy in Sustaining Weight Loss Post-Injectable Incretin Therapy, Presenting a Novel Oral Option

Teuku Ryan May 14, 2026 0

On May 13, 2024, at the 33rd European Congress on Obesity (ECO) held in Istanbul, Türkiye, groundbreaking Phase 3b trial…

Read More
Pharmaceutical R&D

Novel Combination Therapy CagriSema Demonstrates Promising Results in Obesity Management with Preserved Muscle Strength

Teuku Ryan May 13, 2026 0

On 12 May 2026, at the 33rd European Congress on Obesity (ECO) in Istanbul, Türkiye, groundbreaking findings from the Phase…

Read More
Advancing Sustainable Energy Through Predictive Modeling of Polyheptazine Imide Photocatalysts for Solar Fuel ProductionMitochondrial Energy Restoration Offers Potential Breakthrough in Addressing Cognitive Decline and Dementia ProgressionClosing the information gap: ETH Zürich team integrates function and binding in one drug screening assayEarly Behavioral Markers in Midlife Predict Lifespan in Short-Lived Fish, Offering Insights into Human Aging
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactLLMOps in 2026: The 10 Tools Every Team Must HaveThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ